Table SI. Response criteria.

Patients	Tumor size (mm) baseline	Treatment regimen 1st line	Tumor size (mm)	Tumor response	Treatment regimen 2nd line	Tumor size (mm)	Tumor response
1	27.6	DTX (75) x2	37.1	PD	FEC (100) x6	11.6	PR
2	36.3	FEC (100) x6	21.8	SD	DTX (75) x4	39.2	PD
3	55.6	FEC (100) x4	6.0	PR	DTX (75) x4	17.9	PD
4	58.5	AC x 4	10.7	PR	Weekly PTX x12	29.7	PD
5	91.2	FEC (100) x4	25.8	PR	Weekly PTX x6	50.8	PD
6	18.4	DTX (75) x3	28.0	PD	FEC (100) x6	16.0	PR

AC, doxorubicin + cyclophosphamide; DTX, docetaxel; FEC, fluorouracil + epirubicin + cyclophosphamide; PTX, paclitaxel; PR, partial response; PD, progressive disease.

Table SII. Clinicopathological characteristics of patients.

Characteristics	All patients (%)	Samples for mRNA analysis (%)	P-value
No. of patients	1,707	119	
Age (years)			
Mean ± SD	56±13.2	49.0±9.4	
Range	25-95	26-70	
Histology			
Invasive ductal carcinoma	989 (58)	103 (87)	
Invasive lobular carcinoma	47 (3)	5 (4)	
Ductal carcinoma *in situ*	196 (11)	0 (0)	
Other special types	475 (28)	11 (9)	<0.0001[a]
Tumor size			
≤2.0	788 (46)	54 (45)	
2.1-5.0	647 (38)	54 (45)	
>5.0	139 (8)	8 (7)	
Unknown	133 (8)	3 (3)	0.11
No. of positive lymph nodes			
0	960 (56)	35 (29)	
1-3	309 (18)	60 (50)	
4-9	88 (5)	14 (12)	
≥10	48 (3)	9 (8)	
Unknown	302 (18)	1 (1)	<0.0001[a]
Nuclear grade			
1	544 (32)	33 (28)	
2	333 (20)	27 (23)	
3	517 (30)	55 (46)	
Unknown	313 (18)	4 (3)	<0.0001[a]
ER (Allred score)			
Positive (3-8)	1339 (78)	99 (83)	
Negative (0-2)	294 (17)	19 (16)	
Unknown	74 (4)	1 (1)	0.15
PgR (Allred score)			
Positive (3-8)	1126 (66)	82 (69)	
Negative (0-2)	507 (30)	33 (28)	
Unknown	74 (4)	4 (3)	0.76
HER2 (Hercep test)			
0, 1+	1155 (68)	92 (77)	
2+	84 (5)	8 (7)	
3+	156 (9)	16 (13)	
Unknown	312 (18)	4 (3)	0.0003[a]

[a]P<0.05. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PgR, progesterone receptor.